Zacks Research Has Pessimistic Outlook of PBH Q1 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research reduced their Q1 2027 earnings per share (EPS) estimates for Prestige Consumer Healthcare in a research report issued on Tuesday, February 24th. Zacks Research analyst Team now forecasts that the company will earn $1.09 per share for the quarter, down from their previous forecast of $1.24. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2027 earnings at $4.77 EPS, Q2 2028 earnings at $1.30 EPS, Q3 2028 earnings at $1.26 EPS and FY2028 earnings at $5.06 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. During the same quarter in the previous year, the business posted $1.22 EPS. The company’s revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS.

Other analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Jefferies Financial Group lowered their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Hold” and a consensus price target of $80.60.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $69.30 on Friday. The business’s 50-day moving average price is $65.26 and its two-hundred day moving average price is $63.47. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The stock has a market cap of $3.28 billion, a PE ratio of 18.33, a P/E/G ratio of 2.18 and a beta of 0.43.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. The trade was a 2.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in PBH. Dimensional Fund Advisors LP raised its holdings in shares of Prestige Consumer Healthcare by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock valued at $161,723,000 after acquiring an additional 119,459 shares in the last quarter. State Street Corp increased its position in Prestige Consumer Healthcare by 1.4% during the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after purchasing an additional 27,721 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Prestige Consumer Healthcare by 1.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after purchasing an additional 21,085 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Prestige Consumer Healthcare by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after purchasing an additional 9,455 shares during the period. Finally, Morgan Stanley boosted its stake in shares of Prestige Consumer Healthcare by 6.3% during the 4th quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after purchasing an additional 71,078 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Key Stories Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group reported a new purchase of 10,912 PBH shares (~$681,000), signaling fresh institutional buying interest in the stock. Bleakley Investment
• Positive Sentiment: Zacks bumped a few quarterly estimates: Q4 2026 was raised to $1.59 (from $1.54), Q3 2027 to $1.21 (from $1.20) and Q4 2027 to $1.32 (from $1.26) — small upside revisions that suggest pockets of strength in certain quarters.
• Neutral Sentiment: Zacks Research continues to carry a “Hold” rating on PBH even as it updates estimates; the firm’s commentary so far is a recalibration of numbers rather than a rating change. Consensus full‑year EPS referenced by Zacks remains near $4.50 for the current year.
• Negative Sentiment: Zacks pared several near‑term and fiscal forecasts, which is the main driver of downward pressure: Q1 2027 EPS cut to $1.09 (from $1.24), Q1 2028 to $1.14 (from $1.26), Q2 2028 to $1.30 (from $1.33), Q3 2028 to $1.26 (from $1.28), FY2027 to $4.77 (from $4.84) and FY2028 to $5.06 (from $5.19). Those trims signal slower expected earnings growth and likely explain why the stock is underperforming today.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).